Updated from 2:31 p.m. EDT
Mixed earnings results, expectations and announcements continued to drive an uneven response in the biotech and health care sector Thursday.
Among the winners,
( AGIX) climbed 6 cents, or 2.2%, to $2.90 following an earnings release Thursday. The company reported a net loss that narrowed by 34.2% compared with the same quarter in 2006. The company's net loss per share was 32 cents; analysts surveyed by Thomson Financial had estimated that the company would lose 39 cents a share.
( CEPH) announced on Wednesday that it expects first-quarter earnings per share to exceed previously issued guidance by 50%, driven by lower expenses and stronger-than-expected sales. Shares jumped by $5.12, or 6.8%, to $80.42.
Losing ground Thursday was
, which released disappointing earnings late Wednesday. The company saw a 6.9% decrease in revenue from a year ago, and shares dropped $3.59, or 11.4%, to $27.88.
( ZOLL) shares fell $3, or 10.5%, to $25.50 after it reported earnings beating Wall Street's estimates but showed revenue shy of targets.
first-quarter results included a steep decline in profit, driven by a decline in license fees and milestone revenue, but results were in line with analysts' expectations. Its share price closed up 74 cents, or 1.7%, to $43.49.
Other stocks that were down, even after reporting smaller-than-expected losses, included
( CRA), which fell 19 cents, or 1.3%, to $14.11, and
( MLNM), which fell 32 cents, or 2.7%, to $11.64.
Affimetrix and Millennium Pharma helped to drive down the Amex Biotechnology Index, which lost 0.1%.
was down 47 cents, or 1.6%, to $29.23, following earnings that show that first-quarter profit is down and that the company missed estimates.
Earnings were not the only market movers Thursday.
rose 31 cents, or 13.3%, to $2.65 following an announcement that preliminary results from a phase III clinical trial of a gel for the prevention of preterm birth were positive.
announced Thursday it is mulling alternatives for its immunotherapy program, including partnering the business with another company or spinning it out for an equity interest in a newly-formed immunotherapy company. Shares were up 27 cents, or 3.5%, to $7.94.
, a developer of implantable lenses and related ophthalmic products, announced the pricing of an underwritten public offering of 3.1 million shares of its common stock for $5 a share on Thursday. Its stock was up 10 cents, or 2%, to $5.11, following the announcement.